ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2322

Post–Hoc Analysis Showing Better Clinical Response With The Loading Dose Of Certolizumab Pegol In Japanese Patients With Active Rheumatoid Arthritis

Tsutomu Takeuchi1, Kazuhiko Yamamoto2,3, Hisashi Yamanaka4, Naoki Ishiguro5, Yoshiya Tanaka6, Katsumi Eguchi7, Akira Watanabe8, Hideki Origasa9, Mariko Kobayashi10, Toshiharu Shoji10, Nobuyuki Miyasaka11 and Takao Koike12, 1Department of Rheumatology, Keio University, Tokyo, Japan, 2Department of Allergy and Rhaumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 3University of Tokyo, Tokyo, Japan, 4Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 5Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, 6The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 7Sasebo City General Hospital, Sasebo, Nagasaki, Japan, 8Tohoku University, Sendai, Japan, 9Division of Biostatistics and Clinical Epidemiology, University of Toyama School of Medicine, Toyama, Toyama, Japan, 10UCB Pharma, Tokyo, Japan, 11Tokyo Medical and Dental University, Tokyo, Japan, 12Rheumatology, NTT Sapporo Medical Center, Sapporo, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, certolizumab pegol and rheumatoid arthritis (RA), Japanese

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy III

Session Type: Abstract Submissions (ACR)

Background/Purpose: Certolizumab pegol (CZP) with MTX (J-RAPID; NCT00791999) and without MTX (HIKARI; NCT00791921) has demonstrated rapid and sustained improvements in disease activity in Japanese patients (pts) with active rheumatoid arthritis (RA) in placebo-controlled, double-blind (DB), randomized studies1,2. Based on these and previous studies, the recommended dose of CZP includes subcutaneous initial loading dose (LD) of 400mg at Weeks (wks) 0, 2 and 4 followed by 200mg every 2 wks (Q2W). Nevertheless, benefits of LD have never been directly demonstrated in a clinical study. We hereby report safety and efficacy of CZP, with and without LD, from two Japanese studies.

Methods: Data from J-RAPID and HIKARI were used for this analysis; pts eligible to enter open-label extension (OLE) studies at Wk16 or Wk24 received CZP 200mg Q2W or CZP 400mg Q4W without LD (label dose). In J-RAPID DB study, 316 pts were randomized to CZP 100, 200 or 400mg + MTX with initial LD or placebo + MTX Q2W for 24 wks. In HIKARI DB study, 230 pts were randomized to CZP 200mg with LD or placebo Q2W for 24 wks.

Safety and efficacy in pts who received CZP 200mg Q2W with LD during DB phases (LD group: n=82 J-RAPID; n=116 HIKARI) and pts who received CZP 200mg Q2W without LD during OLE phases after being assigned to placebo in DB phase (No-LD group: n=61 in J-RAPID; n=99 in HIKARI) were directly compared. Mean DAS28(ESR) in No-LD groups at OLE baseline were slightly lower than DB baseline (5.8 vs 6.5 J-RAPID; 6.2 vs 6.3 HIKARI). ACR response rates, DAS responses and development of anti-CZP antibodies (Abs) were assessed during 24 wks after initiating CZP. ACR responses were determined using non-responder imputation. Safety population consisted of 1) all pts who received CZP in DB (n=239), 2) LD group and 3) No-LD group. Adverse events were reported both within DB and OLE.

Results: No-LD group showed delayed initial kinetics of ACR20/50/70 responses and sustained lower response to Wk24 (ACR50/70) compared to LD group (Figure). Development of anti-CZP Abs was observed more frequently in No-LD group than LD group (J-RAPID: n=4 [6.6%] vs n=1 [1.2%]; HIKARI: n=27 [27.3%] vs n=18 [15.5%]). Similar safety profiles were reported between No-LD and LD groups during CZP administration period (incidence rates per 100 pt-years; any AEs: 299.2 vs 310.5 J-RAPID, 312.9 vs 308.6 HIKARI; any serious AEs: 17.9 vs 13.4 J-RAPID, 23.0 vs 21.5 HIKARI).

Conclusion: While comparison of DB and OLE data has limitations, administration of CZP loading dose over the first 24 wks is associated with more rapid onset of efficacy, development of lower Ab levels and sustained response compared with initiating CZP without loading dose. These results suggest administration of CZP loading dose improves clinical response in active RA pts with similar safety profile.

References:

1. Yamamoto K. Arthritis Rheum 2011;63(Suppl10):S474; 2. Yamamoto K. Arthritis Rheum 2011;63(Suppl10):S476


Disclosure:

T. Takeuchi,

AstraZeneca, Eli Lilly, Novartis, Mitsubishi-Tanabe and Asahi Kasei,

5,

Abott, Astellas, BMS, Chugai, Daiichi-Sankyo, Eisai, Janssen, Mitsubishi-Tanabe, Nippon Shinyaku, Otsuka, Pfizer, Sanofi-Aventis, Santen, Takeda and Teijin,

2,

UCB Pharma, Abbott, BMS, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Pfizer and Takeda,

8;

K. Yamamoto,

UCB Pharma, Pfizer, Abbott, BMS, Roche, Chugai, Mitsubishi-Tanabe and Eisai,

5,

UCB Pharma, Pfizer, Abbott, Santen, Mitsubishi-Tanabe and Eisai,

2;

H. Yamanaka,

UCB Pharma, Abbott, Astellas, BMS, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Pfizer and Takeda,

2,

UCB Pharma, Abbott, Astellas, BMS, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Pfizer and Takeda,

5;

N. Ishiguro,

Takeda, Mitsubishi-Tanabe, Astellas, Chugai, Abbott, BMS, Eisai, Janssen, Kaken and Pfizer,

2,

Takeda, Mitsubishi-Tanabe, Astellas, Chugai, Abbott, BMS, Eisai, Janssen, Kaken, Pfizer, Taisho-Toyama and Otsuka,

8;

Y. Tanaka,

BMS, MSD, Chugai, Mitsubishi-Tanabe, Astellas, Abbvie, Daiichi-Sankyo,

2,

UCB, Mitsubishi-Tanabe, Abbott, Abbvie, Eisai, Chugai, Janssen, Pfizer, Takeda, Astellas, Daiichi-Sankyo, GSK, AstraZeneca, Eli Lilly, Quintiles, MSD, Asahi Kasei,

8,

UCB, Mitsubishi-Tanabe, Abbott, Abbvie, Eisai, Chugai, Janssen, Pfizer, Takeda, Astellas, Daiichi-Sankyo, GSK, AstraZeneca, Eli Lilly, Quintiles, MSD, Asahi Kasei,

5;

K. Eguchi,

UCB Pharma,

5;

A. Watanabe,

Daiichi-Sankyo, Kyorin, Shionogi, Taisho, Dainippon-Sumitomo, Taiho, Toyama Chemical and Meiji Seika,

2,

MSD, GSK, Shionogi, Daiichi-Sankyo, Taisho-Toyama, Dainippon-Sumitomo, Mitsubishi-Tanabe, Pfizer,

8;

H. Origasa,

UCB Pharma and Astellas,

5;

M. Kobayashi,

UCB Pharma,

3;

T. Shoji,

UCB Pharma,

3;

N. Miyasaka,

Pfizer, Takeda, Mitsubishi-Tanabe, Chugai, Abbott, Eisai and Astellas,

2;

T. Koike,

UCB Pharma, Pfizer, Chugai, Abbott, Mitsubishi-Tanabe, Takeda, Eisai, Santen, Astellas, Taisho-Toyama, BMS, Teijin and Daiichi-Sankyo,

8.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/post-hoc-analysis-showing-better-clinical-response-with-the-loading-dose-of-certolizumab-pegol-in-japanese-patients-with-active-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology